RaQualia Pharma Inc.
4579.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | ¥3,108 | ¥1,901 | ¥2,918 | ¥2,776 |
| % Growth | 63.5% | -34.8% | 5.1% | – |
| Cost of Goods Sold | ¥626 | ¥245 | ¥232 | ¥321 |
| Gross Profit | ¥2,482 | ¥1,656 | ¥2,686 | ¥2,456 |
| % Margin | 79.9% | 87.1% | 92.1% | 88.4% |
| R&D Expenses | ¥1,704 | ¥1,372 | ¥1,249 | ¥1,127 |
| G&A Expenses | ¥991 | ¥621 | ¥572 | ¥620 |
| SG&A Expenses | ¥991 | ¥621 | ¥572 | ¥620 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥1 | ¥0 | ¥0 |
| Operating Expenses | ¥2,695 | ¥1,994 | ¥1,820 | ¥1,748 |
| Operating Income | -¥213 | -¥337 | ¥866 | ¥708 |
| % Margin | -6.9% | -17.7% | 29.7% | 25.5% |
| Other Income/Exp. Net | -¥144 | ¥43 | -¥15 | ¥173 |
| Pre-Tax Income | -¥358 | -¥294 | ¥851 | ¥881 |
| Tax Expense | ¥137 | ¥30 | ¥128 | ¥125 |
| Net Income | -¥495 | -¥324 | ¥723 | ¥756 |
| % Margin | -15.9% | -17% | 24.8% | 27.2% |
| EPS | -22.87 | -14.98 | 34.5 | 36.07 |
| % Growth | -52.7% | -143.4% | -4.4% | – |
| EPS Diluted | -22.87 | -14.98 | 34.47 | 36.04 |
| Weighted Avg Shares Out | 22 | 22 | 21 | 21 |
| Weighted Avg Shares Out Dil | 22 | 22 | 21 | 21 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥8 | ¥10 | ¥14 | ¥23 |
| Interest Expense | ¥184 | ¥7 | ¥6 | ¥1 |
| Depreciation & Amortization | ¥402 | ¥176 | ¥148 | ¥142 |
| EBITDA | ¥188 | -¥112 | ¥1,005 | ¥1,024 |
| % Margin | 6.1% | -5.9% | 34.4% | 36.9% |